Founded in 2008 and based in Lubbock, Texas, CerRx Inc. is dedicated to the discovery and development of innovative anticancer drugs. The company's core mission is to provide effective cancer treatments through unique drug formulations. CerRx's primary products include Fenretinide, a synthetic molecule that increases ceramide waxes to kill cancer cells, and Safingol, an artificial ceramide precursor that enhances the efficacy of Fenretinide. The company focuses on addressing unmet needs in cancer therapy, aiming to improve patient outcomes with novel treatment options.

CerRx has garnered attention for its pioneering approach in the oncology sector. Notable figures associated with the company include its founders and key researchers who have contributed significantly to its drug development programs. The company has achieved significant milestones in preclinical and clinical trials, showcasing the potential of its therapies to combat various forms of cancer. Through its innovative treatments, CerRx has made a meaningful impact on the field of cancer research and continues to work towards transforming cancer care.